Fig. 1.
CpG ODN administration can protect naive mice against AML-induced lethality.
B6 mice (n = 10 per group) were treated with the indicated CpG ODN (100 μg/dose) intraperitoneally beginning on day −2 prior to intravenous C1498 (2 × 105 cells/mouse) infusion according to the schedule described in “Materials and methods.” CpG ODN-treated mice had a significant (P < .008) increase in survival rates as compared with nontreated or complete Freund adjuvant-treated controls. Recipients of CpG 1826 or 2006 ODNs had comparable survival that was superior (P ≤ .001) to CpG 1585-treated recipients.
